Experience

Life Science Editors

• United States
• Writing and Editing
• 1 - 100 Employee

• Scientific Editor

  • Jun 2022 - Present



Helmholtz Institute Würzburg (HIRI)

• Germany
• Research Services
• 1 - 100 Employee

• Scientific Writer

  • Sep 2021 - Present



Springer Nature Group

• Book and Periodical Publishing
• 700 & Above Employee

• Senior Editor at Nature Structural & Molecular Biology

  • Sep 2018 - Jul 2021

• Senior Editor at Nature Structural & Molecular Biology

  • Sep 2016 - Sep 2018



Nature Portfolio

• United Kingdom
• Book and Periodical Publishing
• 300 - 400 Employee

• Associate Editor at Nature Structural & Molecular Biology

  • May 2014 - Sep 2016

• Associate Editor at Nature Communications

  • Oct 2013 - May 2014



The EMBO Journal

• Heidelberg, Germany

• Scientific Editor

  • Mar 2012 - Sep 2013



The Netherlands Cancer Institute

• Netherlands
• Research Services
• 400 - 500 Employee

• Postdoctoral Fellow

  • Oct 2004 - Mar 2012

  My postdoctoral study was concerned with how stem cells commit to a specific fate and how this differentiated state is maintained. Specifically, I investigated the regulation of the “Polycomb”-group of epigenetic silencers during neural differentiation. This proteomics-based approach aimed to provide insights into the existence of various, functionally distinct Polycomb-complexes and their role in ES cell pluripotency and neural commitment. Publications Sparmann A, Van Lohuizen, M. (2006). Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6(11):846-56 Sparmann A, Xie Y, Verhoeven E, Vermeulen M, Lancini C, Gargiulo G, Hulsman D, Mann M, Knoblich JA, van Lohuizen M. (2013). The chromodomain helicase Chd4 is required for Polycomb-mediated inhibition of astroglial differentiation. EMBO J. 32(11):1598-612 Show less



Stony Brook University

• United States
• Higher Education
• 700 & Above Employee

• Graduate Student

  • 1998 - 2004

  My dissertation research focused on interactions between tumor cells and their tissue environment that are essential determinants in the development of malignancy. We demonstrated that constitutive Ras signaling induces secretion of the inflammatory mediator Interleukin-8, which promotes tumor-associated inflammation and neo-vascularization thereby driving tumor growth. Our data identified a novel mechanism by which the Ras oncogene elicits a stromal response that fosters cancer progression. Publications Sparmann A, Bar-Sagi D. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6(5):447-58 Sparmann A, Bar-Sagi D. (2005). Ras oncogene and inflammation: partners in crime. Cell Cycle. 4(6):735-6. Show less